Showing 20 of 41 recruiting trials for “juvenile-myelomonocytic-leukemia”
Optimum Induction Therapy of Low-risk APL
👨⚕️ Xiaolu Zhu, Doctor, Peking University People's Hospital📍 1 site📅 Started Jan 2023View details ↗
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
👨⚕️ John Pimanda, Professor, University of New South Wales📍 5 sites📅 Started Dec 2022View details ↗
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
👨⚕️ Seth Karol, MD, St. Jude Children's Research Hospital📍 89 sites📅 Started Oct 2022View details ↗
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Mar 2022View details ↗
RecruitingNCT04897490 ↗
RWE of 1st Line Treatment With ATO/ATRA for Adult APL
👨⚕️ María José Mela Osorio, Dr., Grupo Argentino de Tratamiento de la Leucemia Aguda📍 6 sites📅 Started Mar 2021View details ↗
Frontline Oral Arsenic Trioxide for APL
Study to Evaluate the Safety and Tolerability of EP0042
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
👨⚕️ Anna Halpern, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Mar 2020View details ↗
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
👨⚕️ Fanco Locatelli, Prof, Dept. of Pediatric Hematology Oncology - Bambino Gesù Children's Hospital Rome📍 31 sites📅 Started Oct 2019View details ↗
Combining Active and Passive DNA Hypomethylation
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
👨⚕️ Mary-Elizabeth Percival, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Nov 2018View details ↗
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →